2,5-Dimethylbromobenzene

We are 2,5-Dimethylbromobenzene CAS:553-94-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,5-Dimethylbromobenzene
CAS.NO:553-94-6
Synonyms:2,5-Dimethylbromobenzene
2-Bromo-1,4-dimethylbenzene
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 199.5±0.0 °C at 760 mmHg
Melting Point 9-10 °C(lit.)
Molecular Formula C8H9Br
Molecular Weight 185.061
Flash Point 80.1±13.1 °C
Vapour Pressure 0.5±0.3 mmHg at 25°C
Index of Refraction 1.544
 
Specification:
Appearance:Cololrless to light yellow liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.

2,5-Dimethylbromobenzene


Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.1280210-80-1 The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.2,2'-Dibromodiethyl ether Massachusetts state health officials, in conjunction with Massport, local health departments, and other medical partners, have responded to prevent the spread of the virus.1-fluoro-3-chloropropane CAS:462-38-4 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.

Related Products
Product Name
3-Hydroxy-2′-methyl-2-naphthanilide View Details
Z-Ndelta-Boc-L-ornithine View Details
2,3-Dichloro-5,6-dicyano-1,4-benzoquinone View Details
S-2-Benzothiazolyl (Z)-2-(5-amino-1,2,4-thladlazol-3-yl)-2-MethoxylMino thioacetate manufacturer H-HIS-GLY-GLY-OH manufacturer 2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methylpropanoic acid manufacturer 1-(p-Toluenesulfonyl)-3-nitro-1,2,4-triazole manufacturer 2-(Carbobenzoxyamino)-1-ethanol manufacturer